Candriam SCA’s Akebia Therapeutics AKBA Stock Holding History

Candriam SCA’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-70,000	Closed	-$176K	–	809
2020 Q3	$176K	Sell	70,000 -1,159,346	-94%	-$10.2M	﹤0.01%	761
2020 Q2	$16.7M	Buy	+1,229,346	New	+$12.7M	0.18%	144
2019 Q4	–	Sell	-300,000	Closed	-$1.18M	–	788
2019 Q3	$1.18M	Hold	300,000	–	–	0.02%	581
2019 Q2	$1.45M	Hold	300,000	–	–	0.02%	583
2019 Q1	$2.46M	Hold	300,000	–	–	0.03%	453
2018 Q4	$1.66M	Buy	300,000 +230,000	+329%	+$1.8M	0.03%	496
2018 Q3	$618K	Buy	+70,000	New	+$626K	0.01%	687
2015 Q1	–	Sell	-76,485	Closed	-$890K	–	636
2014 Q4	$890K	Buy	+76,485	New	+$1.1M	0.02%	453

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Candriam SCA's AKBA Position: Q4 2020 in Review

Candriam SCA sold out of Akebia Therapeutics (AKBA) in Q4 2020, closing a stake of 70,000 shares — an estimated $176K sold.

Candriam SCA first reported a position in AKBA in Q4 2014 and held it in 8 quarters. The position peaked at $16.7M in Q2 2020. 143 funds tracked by Wall St. Rank hold AKBA as of Q4 2020.

Candriam SCA reported no remaining Akebia Therapeutics position as of Q4 2020 after selling out during the quarter.
Candriam SCA sold 70,000 Akebia Therapeutics shares in Q4 2020, an estimated $176K.
Candriam SCA first reported a position in Akebia Therapeutics in Q4 2014 and held it in 8 quarters.
Candriam SCA's Akebia Therapeutics position peaked at $16.7M in Q2 2020.
143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.